New drug trial aims to protect kidneys from scarring disease

This research study is testing whether regular injections of an investigational drug called APL2 can help control focal segmental glomerulosclerosis (FSGS), a serious kidney disease that causes scarring. The study will involve about 270 adults and teenagers with FSGS to see if the treatment reduces protein in their urine and helps preserve kidney function over time. The trial has two parts: first an open-label phase where all participants get the drug, followed by a placebo-controlled phase where some receive APL2 and others receive dummy injections.